Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

The State Research Center of Virology and Biotechnology “VECTOR” of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide-based antiviral vaccine for mass immunization in i...

Full description

Bibliographic Details
Main Authors: Alexander B. Ryzhikov, Evgeny A. Ryzhikov, Marina P. Bogryantseva, Svetlana V. Usova, Elena A. Nechaeva, Elena D. Danilenko, Stepan A. Pyankov, Andrey S. Gudymo, Anastasiya A. Moiseeva, Galina S. Onkhonova, Oleg V. Pyankov, Ekaterina S. Sleptsova, Nikita V. Lomakin, Veronika S. Vasilyeva, Mikhail V. Tulikov, Vitaly G. Gusarov, Andrey A. Pulin, Maria A. Balalaeva, Svetlana B. Erofeeva, Stanislav A. Terpigorev, Olga A. Rychkova, Ivan M. Petrov, Viktoriia Y. Delian, Vladimir V. Rafalskiy, Sergey V. Tyranovets, Elena V. Gavrilova, Rinat A. Maksyutov
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19
peptide vaccine
Online Access:https://www.mdpi.com/2076-393X/11/5/998

Internet

https://www.mdpi.com/2076-393X/11/5/998

Similar Items